Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$30.95 - $120.97 $154,750 - $604,850
-5,000 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$21.55 - $96.1 $107,750 - $480,500
-5,000 Reduced 50.0%
5,000 $428,000
Q1 2021

May 10, 2021

BUY
$8.15 - $38.44 $81,500 - $384,400
10,000 New
10,000 $279,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $75.8M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Rkl Wealth Management LLC Portfolio

Follow Rkl Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rkl Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rkl Wealth Management LLC with notifications on news.